Vidofludimus calcium

Drug Profile

Vidofludimus calcium

Alternative Names: IMU 838

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 4SC
  • Developer Immunic
  • Class Amides; Anti-inflammatories; Biphenyl compounds; Carboxylic acids; Cyclopentanes; Disease-modifying antirheumatics; Fluorobenzenes; Phenyl ethers; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Crohn's disease

Most Recent Events

  • 17 Nov 2017 Phase-I clinical trials in Crohn's disease in Germany (PO) (Immune Therapeutics pipeline as of November 2017)
  • 14 Nov 2017 Immunic AG plans the CALDOSE-1 phase II trial for Ulcerative Colitis in Germany (NCT03341962),
  • 28 Sep 2016 Immunic acquires vidofludimus calcium (IMU 838 programme from 4SC (9204497)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top